A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Elizabeth Henry
Loyola Univ. Medical Center
Principal Investigator - Fernando Quevedo, MD
Mayo Clinic
Principal Investigator - Jason Chesney, MD
Brown Cancer Center
Principal Investigator - Jhanelle Gray, MD
Moffitt Cancer Center
Principal Investigator - Laura Chow, MD
University of Washington
Principal Investigator - Lionel Lewis
Dartmouth-Hitchcock Medical Center
Principal Investigator - Martin Voss, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator - Mohamad Salkeni, MD
Mary Babb Randolph Cancer Center
Principal Investigator - Monika Joshi, MD
Penn State Hershey Cancer Institute
Principal Investigator - Omid Hamid, MD
The Angeles Clinic
Principal Investigator - Peter Van Veldhuizen
Menorah Medical Center tour
Principal Investigator - Raid Aljumaily, MD
Peggy Charles Stephenson Cancer Center
Principal Investigator - Robert Alter, MD
John Theurer Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
East Bentleigh, Australia
- Research Site
Frankston, Australia
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Bordeaux, France
- Research Site
Dijon, France
- Research Site
Marseille, France
- Research Site
Paris, France
- Research Site
Villejuif, France
- Research Site
Amsterdam, Netherlands
- Research Site
Groningen, Netherlands
- Research Site
Cambridge, United Kingdom
- Research Site
Cardiff, United Kingdom
- Research Site
Southampton, United Kingdom
- Research Site
Los Angeles, California, United States
- Research Site
Tampa, Florida, United States
- Research Site
Overland Park, Kansas, United States
- Research Site
Louisville, Kentucky, United States
- Research Site
Rochester, Minnesota, United States
- Research Site
Hackensack, New Jersey, United States
- Research Site
New York, New York, United States
- Research Site
Cleveland, Ohio, United States
- Research Site
Oklahoma City, Oklahoma, United States
- Research Site
Portland, Oregon, United States
- Research Site
Hershey, Pennsylvania, United States
- Research Site
Nashville, Tennessee, United States
- Research Site
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 May 2014
- Primary completion
- 17 Mar 2020
- Completion
- 17 Mar 2020
- Last update posted
- 1 Jun 2021
- Registered enrollment
- 97
- Registry id
- NCT02118337
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.